MIR1290: MIR1290 is an exosomal miRNA that has been studied in various contexts. In the context of colorectal adenoma (CRA), MIR1290 levels were found to be a significant discriminating factor in identifying CRA in patients [PMC8116025]. In the context of non-alcoholic fatty liver disease (NAFLD), a miRNA panel that included MIR1290 showed high diagnostic accuracy [PMC5910543]. In melanoma cells, MIR1290 was found to be downregulated by POL treatment, and its downregulation promoted melanoma-cell autophagy by regulating the expression of BECN1 [PMC5604572]. MIR1290 levels were also found to be increased in primary melanoma tissues compared to adjacent normal tissues [PMC5604572]. Additionally, MIR1290 has been studied in the context of HIV-1 replication and as a potential marker for early diagnosis of necrotizing enterocolitis (NEC) [PMC9237370] [PMC9523100]. Furthermore, MIR1290 has been implicated in muscle atrophy and as a potential circulating biomarker for pancreatic cancer diagnosis [PMC7958887] [PMC6219528]. The role of MIR1290 in melanoma and ovarian cancer is still not well-studied compared to other tumors, but it has been shown to have oncogenic functions in other human tumors such as gastric cancer and esophageal squamous-cell carcinoma [PMC5604572] [PMC8928998]. The expression levels of MIR1290 have also been associated with SARS-CoV-2 infection and hypoxia-associated extracellular vesicles (EVs) in melanoma patients with poor prognosis. Additionally, it has been reported that combining the expression levels of MIR1290 with CA19-9 improves the effectiveness for selecting patients at risk for pancreatic ductal adenocarcinoma (PDAC) [PMC10057657] [PMC5465008].